BOLD Boundless Bio, Inc. Expected net earnings per share growth this year
Clinical research outsourcing allows Boundless Bio, Inc. (BOLD) to focus on innovation, as evidenced by the annual net income per share trend, where the latest value is recorded as 2.70. Business growth is based on the validation of the ecDNA platform and new patents. Meanwhile, the company complies with environmental regulations for chemical waste disposal, minimizing the footprint of its laboratory developments.
Financial and market metric breakdowns for Boundless Bio, Inc. (BOLD)
- stock value and consensus price forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt and liquidity details:
Debt to Equity Boundless Bio, Inc.|BOLD - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient boundlessbio.com|BOLD - Company Debts|Debts to Book Value Boundless Bio Inc|BOLD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Boundless Bio|Interim Coverage Ratio boundlessbio.com
- earnings and multiples data:
BOLD - Company Net Income|Net Profit Forecast Boundless Bio, Inc.|BOLD - P/E Multiple|Projected Price to Earnings Boundless Bio Inc|BOLD - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Boundless Bio Inc|BOLD - Operating profit EBITDA|Earnings per share for the last twelve months Boundless Bio|BOLD - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months boundlessbio.com|BOLD - Earnings per share growth in current year|Net earnings per share growth forecast for next year Boundless Bio, Inc.
Basic company analysis:BOLD Boundless Bio Inc.
This indicator reflects the year-over-year dynamics of net income per share. Analyzing this rate allows an investor to assess business resilience to market shocks and the efficiency of capital management. The trend, represented by measured EPS YoY growth, reveals acceleration phases in operational processes. For Boundless Bio, Inc. (BOLD), such metrics correlate with investments in R&D personnel specializing in oncogenomics. Retaining key scientists through stock options provides the fundamental basis for future profit growth.
Key competitors
Earnings per share growth rate in current year Tempus Labs (TEM)|Earnings per share growth in current year Qiagen Group|Isis Pharmaceuticals (IONS) - Expected net earnings per share growth this year|Earnings per share growth in current year Repligen Corporation (RGEN)|Expected net earnings per share growth this year aviditybiosciences.com|CRISPR Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year WGS|Ultragenyx Pharma - Earnings growth in current year|BEAM: Earnings per share growth in current year|SRPT: Earnings growth in current year|TWST - Expected net earnings per share growth this year|Earnings per share growth in current year 10x Genomics|Earnings per share growth rate in current year Intellia Therapeutics Inc NTLA|Net earnings per share growth this year STOK (Stoke)|BLFS (BioLife) - Earnings per share increase in current year|Earnings growth in current year WVE (Wave Life Sciences)|Expected net earnings per share growth this year mazetx.com (MAZE)|SION - Earnings per share growth in current year|PRME (Prime Medicine Inc) - Earnings per share growth this year|TSHA: Earnings growth in current year|Net earnings per share growth this year uniQure Pharma|Net earnings per share growth this year MGTX|regenxbio.com (RGNX) - Expected net earnings per share growth this year|Earnings growth in current year SLDB|Earnings per share growth in current year OCGN (Ocugen Inc)|Earnings per share growth in current year Pacific Biosciences of California PACB|Benitec Corp (BNTC) - Earnings per share growth rate in current year|DSGN - Earnings per share growth in current year|RCKT: Earnings per share growth in current year|FDMT: Earnings growth in current year|Earnings per share growth this year LXEO|KRRO (Korro Bio Inc.) - Earnings growth in current year|Earnings per share growth this year EDIT (Editas Corp)|Earnings per share growth in current year Silence Therapeutics (SLN)|proqr.com - Earnings per share growth this year|Earnings growth in current year CDXS (Codexis)|Earnings growth in current year Sangamo Therapeutics Inc. SGMO|Nautilus Biotechnology Inc - Earnings growth in current year|MGX: Earnings per share growth in current year|Precision BioSciences, Inc. (DTIL) - Earnings per share growth in current year|Earnings per share growth rate in current year Generation Bio (GBIO)|Net earnings per share growth this year XCUR|Earnings growth in current year Celsion Corporation|Earnings per share growth in current year Phio Pharmaceuticals (PHIO)|mustangbio.com - Earnings per share growth this year|Earnings growth in current year RNAZ (TransCode Therapeutics, Inc.)|BNGO: Earnings per share growth this year|APDN - Earnings per share growth in current year|BLUE: Earnings per share growth in current year|IPA: Earnings growth in current year|Earnings per share growth rate in current year Omega Therapeutics Corp (OMGA)|Earnings per share growth in current year Singular Genomics Systems|regulusrx.com (RGLS) - Expected net earnings per share growth this year|Earnings per share growth in current year Syros Pharmaceuticals, Inc. (SYRS)|Expected net earnings per share growth this year Telesis Bio Inc.|TRACON - Net earnings per share growth this year|Earnings per share increase in current year UBX
